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Summary Tissue prostaglandin (PG) content and production by human breast cancers were measured in 24
human mammary carcinoma specimens. The 5 compounds studied were PGE1, PGE2, PGF2, 6-keto-PGFic,,
and TXB2. The tissue content of all 5 compounds was higher in neoplastic tissue in comparison with the
paired noncancerous breast tissue. However, microsomal PG synthetase activity in vitro in noncancerous and
neoplastic breast tissue was comparable. Increased thromboxane formation was associated with three clinical
variables-tumour size, axillary lymph node metastases and distant metastasis. A lesion negative for either
oestrogen or progesterone receptor content tended to produce more TXB2 but lower PGE2 and 6-keto-
PGF1a,. Results obtained in this pilot study may provide clues as to what direction future larger studies could
take in the search for reliable prognostic indicators for breast cancer.
The evidence linking prostaglandins (PGs),
particularly of the E series, to human mammary
cancer is substantial, and this topic has been
reviewed previously (Bennett, 1979; Karmali, 1980).
In this disease excess prostaglandin E production
by tumours appears to be responsible for
occasional cases of hypercalcaemia (Seyberth et al.,
1975) and may contribute to the development of
metastatic disease (Rolland et al., 1980). The
survival time after mastectomy was found to
correlate inversely with amounts of "prostaglandin-
like" material extracted from human mammary
cancers (Bennett et al., 1979). The ever-increasing
list of references presenting evidence of enhanced
PG content and synthetic capacity in many human
tumours of different types therefore makes the
reasons for continuing to study PGs in cancer
compelling.
Recent studies suggest that the many
physiological and pathological effects formerly
attributed to the classical PGs, namely, PGE2 and
PGF2a, may in fact be attributable to the action of
other oxygenated metabolites of arachidonic acid,
including thromboxanes, prostacyclin and other
potentially important prostanoids.
We report here a comparison of tissue content
and biosynthesis of PGE1, PGE2, PGF2a, 6-keto-
PGF15, (a stable degradation product of PGI2) and
TXB2 (a stable degradation product of
thromboxane A2) in a series of 24 human
mammary carcinomas. PG and TXB2 production in
each specimen was examined in relation to tumour
size, axillary lymph node metastases, distant
metastasis and hormone status (oestrogen and
progesterone).
Materials and methods
The study concerns 24 patients referred to the
Memorial Sloan-Kettering Cancer Center, New
York for evaluation and treatment of breast
masses. All biopsies, primary surgical procedures,
pathological evaluation and procurement of the
specimens were made at the Center. Tissues for
prostaglandin studies were obtained immediately
after the patient underwent the initial surgical
procedure. Approximately 2g each of the tumour
mass and its paired noncancerous ductal tissue
from the same specimen were delivered promptly to
the laboratory by staff of the Tumour Procurement
Center. Analyses of prostaglandin yields (tissue
content plus any metabolism occurring during the
processing procedures) and prostaglandin
synthetase activity were carried out immediately or
after storage at -70°C.
The patients underwent initial clinical staging and
all abnormalities were further evaluated with X-
rays, radionuclide scans and, if necessary, from
biopsies. The clinical and pathological staging
accorded with the Classification of the American
Joint Committee for Cancer Staging (1979). The
results are shown in Table I. All were infiltrating
ductal adenocarcinomas except for patient No. 20,
who had invasive lobular carcinoma. Histology of
the noncancerous control specimens showed no
evidence of chronic mastitis, fibrocystic disease or
presence of inflammatory cells, and were reported
to be normal.
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Table I Clinical information about 24 breast carcinomasa' b
Distant
Tumour size No. of +vel metastases
Oestrogen Progesterone (largest diameter) total bone, liver
Patient Age receptorc receptorc cm lymph nodes or lung Stage
1 60 + + 3 0/23 II
2 50 19 15/31 + IV
3 67 + + 4 14/15 + IV
4 59 + 6.5 0/23 III
5 52 6.5 4/19 III
6 45 5.5 10/30 III
7 60 + + 2.2 0/32 II
8 55 12 12/12 + IV
9 57 + + 4 3/25 II
10 56 4 15/16 + IV
11 72 8 31/31 + IV
12 36 4.8 0/32 II
13 67 + 1.6 0/22 I
14 54 5 10/27 + IV
15 39 + 1/28 II
16 73 3.5 14/18 IV
17 38 11 17/18 + IV
18 49 + + 3 0/22 II
19 44 + 3.5 1/20 II
20 69 + + 3 2/25 + IV
21 51 8 4/27 IV
22 31 8.5 10/19 III
23 52 5.5 2/21 II
24 71 + 3 5/15 II
aThe 24 cases of human mammary cancers in this study were patients referred for
evaluation and treatment to the Memorial Sloan-Kettering Cancer Center, New York, N.Y.
bPost-surgical treatment pathology classification of the UICC-AJC 1977.
cThe cutoff point at which the specimen was considered positive for oestrogen or
progesterone was 6fmolmg-1 protein.
Prostaglandin measurement procedures
Materials Prostaglandin standards PGE1, PGE2,
PGF2. tromethamine salt, 6-keto-PGFia and TXB2
were kindly supplied by Dr. J. Pike (Upjohn
Company, Kalamazoo, Michigan). Tritium-labelled
compounds were purchased from New England
Nuclear (Boston, Massachusetts). Rabbit antisera
to PGE1 and PGE2 were obtained from the Pasteur
Institute (Paris, France). Antibodies to PGF2., 6-
keto-PGFIa and TXB2 were raised in our
laboratory (R.K.). The cross-reactivities of these
antibodies for the nontargeted PGs were no greater
than 4% except for PGE1 and PGE2 antisera
which cross-reacted 10% with PGE2 and PGE1
standards, respectively. Unlabelled arachidonic acid
(Grade 1) was obtained from Sigma (St. Louis,
Missouri).
Analytical methods-Extraction The procedure for
extracting the prostaglandins was described earlier
(Karmali et al., 1982). Briefly, a trace of [3H]-PG
was added to aliquots of standards and samples
before being extracted once with 3.5ml petroleum
ether. After acidification to pH 3.5, the samples
were extracted twice with diethyl ether, dried under
nitrogen and reconstituted in assay buffer. The
efficiency of the extraction procedure to this point
was 85-95%.
Radioimmunoassay (RIA) Standard quantities of
each prostaglandin (0-10OOpg) or the extracted
sample to be measured were prepared in 0.1 ml
aliquots of assay buffer. Antiserum and label were
added successively in 0.1 ml aliquots and incubated
at 4°C for 8-12h. Bound and free [3H]-PG were
separated by 0.5ml dextran-coated charcoal (0.5-
1.0% by wt) to estimate the amount of each
compound in the unknown samples.
The sensitivity of the assays has been found to be
- 10 pg. The intra-assay coefficient of variation was
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Assay ofprostaglandin-like material extractedfrom
mammary tissue Solid tumour fragments weighing
between 0.5 and 1 g were ground using a mortar
and pestle at 2°C in a 1:5 (g:ml) tissue:buffer
volume of MES buffer (1 M 2n-morpholino-ethane
sulphonic acid, pH 7.4, containing 2mM CaC12,
2% glycerol and 1 mM monothio-glycerol). No
antioxidant was added to avoid altering the PG
synthetase. Homogenates were centrifuged at 800g
for 15min at 4°C. Each supernatant thus obtained
was further spun at 150,000g for 1 h at 4°C and
stored in duplicate at -20°C. After adding [3H]-
PGE2 as a tracer, the PGs were extracted and
measured by RIA as described above. Such
measurements represent the yield of the 5 immuno-
reactive compounds in noncancerous and tumour
tissues. The remaining microsomal pellet obtained
after centrifugation at 150,000g was saved for
prostaglandin synthetase studies.
Prostaglandin synthetase assay The microsomal
pellet was suspended in MES buffer; its protein
content was measured by the Lowry method and
adjusted to 0.5mg protein ml-' in MES buffer.
Biosynthesis of PGs by microsomal preparations of
noncancerous and neoplastic mammary tissue was
assayed by a modification of the procedure
described by Rolland et al. (1980).
A 0.2ml aliquot of the microsomal fraction was
incubated at 37°C with 0.8ml MES buffer
containing 1.25mM reduced glutathione, 1.25mM
adrenaline, and 1.25MM sodium arachidonate.
After incubation for 10min, [3H]-PGE2 was added
as a tracer to evaluate procedural losses. PGs were
extracted with a petroleum ether/diethyl ether
mixture as described earlier (Karmali et al., 1982).
The organic extracts were then dried under nitrogen
and taken up in buffer for subsequent measurement
by RIA for PGE1, PGE2, PGF2a, 6-keto-PGF1,
and TXB2.
Statistical analysis The log1o transformation was
applied to tissue PG yields to make the statistical
distributions more nearly Gaussian in order to
apply classical statistical techniques (Student's
paired or two-sample t-test, Pearson correlation
and analysis of variance). Similarly, tumour size
was transformed logarithmically, and the
proportion of positive nodes was logistically
transformed, log (No. of positive nodes + 1/6)/(No.
of negative nodes + 1/6). Microsomal PG synthesis
values were not transformed. The results of
parametric tests were confirmed by their
nonparametric counterparts (Wilcoxon signed rank
test, Mann-Whitney U-test and Kendall rank
correlation) used on the raw values. Student's t-test
was used to compare two groups (e.g., distant
B.J.C. D
metastasis present or absent) and analysis of
variance was applied to test the relationship with
Stage of disease (I, II vs III vs IV). Marginally
significant results must be confirmed on a larger
data set in view of the problem of multiplicity, i.e.,
simultaneous statistical testing of the 5 PGs with
respect to each of the other variables. However,
results of P<0.01 are significant even by the
conservative Bonferroni criterion.
Results
Tissue yields and in vitro production of5 prostanoids
were measured in 24 neoplastic breast lesions and
their associated noncancerous ductal tissues. These
lesions were randomly obtained from breast masses
removed surgically at Memorial Hospital.
Tissue yields ofprostaglandins and thromboxane B2
in noncancerous and neoplastic tissues
The tissue yields (ngg- I wet wt) of all 5
immunoreactive compounds, PGE1, PGE2, PGF2,.I
6-keto-PGF1,, and TXB2, varied widely from lesion
to lesion but the mean values were considerably
higher in breast tumours than the associated
noncancerous breast tissues. The following are
(log1o) values (ngg-1 wet tissue): Mean+s.e. with
noncancerous values followed by tumour values:
PGE1: 0.557+0.076 and 0.777+0.097 (P=0.010);
PGE2: 0.113+0.157 and 0.470+0.150 (P=0.032);
PGF2a: -0.330+0.087 and 0.383+0.120 (P<0.001);
6-keto-PGF1,: -0.360+0.141 and 0.398+0.162
(P<0.001); and TXB2: -0.426+0.103 and 0.186
+0.108 (P<0.001).
Tumour and noncancerous tissue PG yields
correlated significantly with each other (P<0.001).
Noncancerous tissue yields were thus used as
controls to obtain "adjusted" values upon which the
rest of the analysis was based.
The methodology has been tested carefully in our
laboratory using mouse, rat and human mammary
carcinomas to evaluate if PG production results
during the processing of the material. Although this
evaluation has involved processing of a large
number of tumour specimens, data are presented
for PG yield in 5 replicates of only one such
tumour specimen processed at 2°C as described
using MES buffer with or without ibuprofen
(20Mgml-1). The following are mean values (ngg-1
wet tissue) for control followed by samples
processed in the presence of ibuprofen, both at 2°C:
Mean +s.e.: PGEI: 150+7.7. and 167+11.9;
PGE2: 224+30.6 and 192.1 +33.1; PGF2a 8+1-5
and 6+0.4; 6-keto-PGF1,: 22+7.1 and 28+0; and
TXB2: 9+ li. and 10+0.3. There was no significant
difference in tumour yields between control samples692 R.A. KARMALI et al.
and those processed in the presence of ibuprofen
(20Mgml - 1).
The above test was repeated using 5 replicates of
another tumour specimen and the extracted
material was allowed to stand at room temperature
for 60min before centrifuging it. Tumour yields
(ngg- wet tissue) were lower in specimens that
were processed in the presence of 20Mugml-1
ibuprofen in MES buffer: PGE1: 49+8.1 and 21+0
(P=0.026); PGE2: 294+ 11.4 and 166+91.2; PGF2,;
43 +6.3 and 36+8.6; 6-keto-PGF1,: 142+29.9 and
51+15.8 (P=0.054); and TXB2: 7+2.0 and 5+2.0.
These results demonstrate the importance of
maintaining the temperature at 2°C to prevent
production of PGs during the processing of the
material.
Tissue prostaglandin and TXB2 Yields: Tumour
size Adjusted TXB2 yield (tumour-noncancerous
levels) correlated with tumour size (P=0.04) (Table
II). There was no significant correlation between
other prostanoids and tumour size.
Table II Association of adjusted tissue yields of
prostaglandins and the tumour size or the proportion of
positive axillary lymph nodes-Kendall Rank Correlation
Coefficient
Log10(tumour-noncancerous)a
Tumour size Positive nodes
(n =23) (n =24)
PGE1 0.073 0.175
PGE2 0.033 0.066
PGF2,, -0.024 0.109
6-keto-PGFi, 0.029 0.040
TXB2 0.195 (P=0.05) 0.327 (P=0.026)b
aTumour-noncancerous represents the log10 PG levels
(plus any metabolism during the tissue processing) in a
breast tumour minus log1o PG amount measured in the
non-cancerous breast tissue taken from the same breast
mass. The units in this and subsequent tables are log10
ngg 1 wet tissue. The non-cancerous specimen was
collected by the nursing staff in the Pathology Laboratory
under the supervision of the Clinical Pathology Fellow.
bA statistically significant correlation was noted between
adjusted TXB2 levels and the number of positive lymph
nodes.
Tissue prostaglandins and TXB2 Yields: Proportion
of positive axillary lymph nodes The adjusted
tumour TXB2 levels correlated with the proportion
of positive lymph nodes (P=0.026). Adjusted
tumour TXB2 yields were calculated by comparing
TXB2 amounts from tumour tissue with those
found in associated specimens of noncancerous
breast tissue (Table II). Amounts of PGE1, PGE2,
and PGF2a and 6-keto-PGF1, did not correlate
statistically with the proportion of positive nodes.
Tissue prostaglandin and TXB2 yields: Metastases
(bone, lung and liver) There was no significant
relationship between PG yields and presence of
confirmed distant metastases (Table III).
Table III Adjusted tissue yields of prostaglandins and the
spread of tumours to distant metastases (n=7 +ve; n= 17
- ve)a
Log1o (tumour-noncancerous): Mean
+s.e.
+ve metastasis -ve metastasis
PGE1 -0.574+0.399 -0.228+0.098
PGE2 0.039+0.261 -0.488+0.167
PGF2, -0.581+0.187 -0.706+0.125
6-keto-PGF1, -0.838+0.253 -0.645+0.170
TXB2 -0.509+0.163 -0.565+0.147
aThere was no significant relationship between
prostaglandin yields and presence of confirmed distant
metastases.
Tissue prostaglandin and TXB2 yields: Oestrogen
receptor positive or negative When tumour PG
yields were compared with respect to the oestrogen
receptor content, the mean adjusted tumour TXB2
yields (tumour-noncancerous) were significantly
lower in receptor +ve tumours compared with
receptor -ve (P=0.017) (Table IV).
Tissue prostaglandin and TXB2 yields: Progesterone
receptor content Adjusted tumour 6-keto-PGF1,
yields were lower in progesterone +ve than in
progesterone -ve receptor lesions (P=0.066).
Tissue prostaglandin and TXB2 yields: Stage of
malignancy When tumour amounts of 5
compounds were analysed (without adjusting by
subtracting the amounts from paired noncancerous
tissue) in tumours with regard to Stage, PGE2
tended to be higher (P=0.058) and 6-keto-PGF1,
was lower (P=0.009) with advancing Stage. These
results are presented without subtracting the
noncancerous values, for comparison with earlier
studies by Rolland et al. (1980). Data of PGE2 and
6-keto-PGF1, have been presented in Table V; there
was no significant difference in PGE1, PGF2. and
TXB2.
Characterization of microsomal prostaglandin
synthetase activity in noncancerous and neoplastic
breast tissue
The microsomal enzyme obtained from tumour and
noncancerous homogenates generated (ngmg-l
protein/10min, Mean +s.e.): 23.5+3.04 and
25.5+3.48 PGE1; 16.5+2.92 and 14.5+2.56 PGE2;
1.4+0.36 and 3.3+ 1.51 PGF2a; 8.0+ 1.78 and 7.4PROSTAGLANDINS AND BREAST CANCER 693
Table IV Adjusted tissue yields of prostaglandins and oestrogen or progesterone receptor content
Logl0 (tumour-noncancerous) PG content: Mean +s.e.
Oestrogen Oestrogen Progesterone Progesterone
+ve -ve + ve -ve
n 11 13 6 18
PGE1 -0.504+0.260 -0.181 +0.109 -0.736+0.468 -1.932+0.081
PGE2 -0.315+0.214 -0.351+0.208 -0.573+0.350 -0.255+0.158
PGF2a -0.573 +0.127 -0.751 +0.156 -0.670+0.143 -0.669+0.130
6-keto-PGF1a -0.745+0.190 -0.664+0.207 - 1.064+0.177 (P=0.066)a -0.580+0.169
TXB2 -0.850+0.187 (P=0.017)b -0.294+0.091 -0.862+0.329 -0.445+0.098
aTumour 6-keto-PGFIa yields were lower than in non-cancerous tissue in both progesterone +ve and -ve
receptor lesions; however, this difference was greater in the progesterone +ve receptor lesions.
bTumoui TXB2 levels were lower relative to non-cancerous tissue in oestrogen +ve receptor breast lesions in
comparison with receptor -ve lesions.
Table V Tissue yields ofprostaglandins and stage of the breast malignancy
Log PG (mean +s.e.)a
Stage I & II Stage III Stage IV
(n=8) (n=8) (n=7)
PGE2 Tumour: 0.0364+0.2152 (P =0.577)b -0.2614+0.2288 0.6924+0.2390
Tumour-noncancerous:-0.3638 +0.2645 -0.6906+0.2199 0.0258 +0.2629
6-keto-PGF,a Tumour: 0.0907+0.2058 (P=0.009)c - 0.1552+0.2321 -0.7208 +0.1031
Tumour-noncancerous:-0.6335 +0.2187 -0.5400+0.2438 - 1.0628+0.2700
aData on PGE1, PGF2a and TXB2 did not reach statistical significance; they will be provided on
request.
bTumour PGE2 yields in Stage I and II breast lesions tended to be lower than the Stage IV lesions.
cTumour 6-keto-PGF,a yields decreased with advancing Stage of breast malignancy.
+1.49 6-keto-PGFI,a and 2.2+0.31 and 2.5+0.35
TXA2, respectively. Enzyme activity was inhibited
58% when 20 pgml-1 ibuprofen was included in
the incubation mixture. This suggests that much
higher amounts of the inhibitor are required to
bring about 100% inhibition. We have found this
to be the case with mammary tumour cells in vitro
where ibuprofen 100pgml-P of culture medium
were required to prevent PG synthesis (Karmali
and Cohen, unpublished observations). One feature
of the PG synthetase is that while an agent causes a
block in one organ, it will usually cause a block in
another but there may be profound differences in
the concentrations required (Flower, 1974; Flower
& Vane, 1974).
Tumour and noncancerous tissue PG production
in vitro correlated with each other: PGE1
(P <0.001), PGE2 (P <0.001), 6-keto-PGFia
(P <0.001) and TXB2 (P<0.001). Noncancerous
tissue PG yields were thus used as controls to
obtain "adjusted" values upon which the rest of the
statistical analysis is based.
PG synthetase activity: Tumour size The only
significant relationship between tumour size and
adjusted PG production by microsomal PG
synthetase was with TXB2 (P=0.04) (Table VI).
Table VI Association of adjusted prostaglandin activity
in vitro and tumour size or the proportion of positive
axillary lymph nodes-Pearson Correlation Coefficient
Tumour-noncancerous
Tumour size Positive nodes
(n=23) (n=24)
PGE1 0.025 0.118
PGE2 -0.118 -0.080
PGF2,a 0.094 0.149
6-keto-PGFi, 0.012 -0.084
TXB2 0.308 (P=0.040)a 0.356 (P=0.015)b
a.bAdjusted tumour TXB2 synthesis in vitro relative to
non-cancerous tissue was significantly related to tumour
size and number ofpositive nodes.
PG synthetase activity: Proportion of positive
axillary lymph nodes The only significant
correlation between the proportion of positive
nodes and adjusted production by microsomal
enzyme was with TXB2 (P=0.015) (Table VI).694 R.A. KARMALI et al.
PG synthetase activity: Distant metastases (to liver,
bone and lung) Seven lesions had detected positive
distant metastases in the 24 patients studied. None
of the adjusted tumour PG production yields were
significantly different in patients with metastases
compared with those not associated with detected
metastases (Table VII).
Table VII Association of adjusted PG synthetase activity
in vitro and metastasis of breast tumours to lung, bone
and liver (n=7 +ve)a
Tumour noncancerous (mean +s.e.)
Prostaglandin +ve metastasis -ve metastasis
PGE1 23.51+ 14.64 3.31+ 15.72
PGE2 -21.45 +44.66 -19.59+ 9.41
PGF2a 2.75+ 3.37 25.46+20.61
6-keto-PGF1,. -10.20+ 18.96 -5.22+ 5.56
TXB2 5.19+ 2.89 1.01+ 1.30
'There was no
synthetase activity
distant metastases.
significant relationship between PG
in vitro and presence of confirmed
PG synthetase activity: Oestrogen recepor
content Of the 24 breast masses, 11 were receptor
+ve. Adjusted tumour TXB2 production (tumour-
noncancerous tissue) tended to be higher in
receptor -ve breast lesions (P=0.056) (Table
VIII).
PG synthetase activity: Progesterone receptor
content Adjusted tumour PGE2 production
(tumour-noncancerous) in receptor +ve tumour
was higher than in receptor -ve tumours
(P =0.046) (Table VIII), whereas the reverse
occurred with TXB2 (P=0.002).
PG synthetase activity: State of malignancy There
were no significant trends in adjusted microsomal
PG synthesis in vitro with increasing Stage of breast
malignancy.
Discussion
While most of the previous studies in both human
and experimental (Bennett et al., 1975, 1977, 1979)
mammary cancer have reported elevated PGE2
tumour yields, this report demonstrates that other
PG moieties such as PGE1, PGF2., PGI2 and
TXA2 are formed by human mammary cancers. In
addition, noncancerous tissue from the same
resected specimen was studied in an attempt to
compensate for individual variations and to
standardise the methodology to evaluate the extent
of the PG-related abnormality in the malignant
breast specimcii.
The me; amounts of PGs extracted from the
breast !!Iinours were considerably higher than those
in -,,ired noncancerous breast tissue controls. In
si .uies of PGs in breast cancer reported by Kibbey
et al. (1979), PGE2 yields were higher than those
measured in this study, possibly due to
methodological differences.
The present results also show that microsomal
enzyme fractions obtained from both noncancerous
and neoplastic breast tissues can transform
arachidonate (C20:4) to various prostanoids. With
the exception of less PGF2a synthesis by tumour
microsomes, the mean production of the various
PG moieties were comparable in both noncancerous
and neoplastic breast tissues and were in the order
PGE1 >PGE2 >6-keto-PGF1 ,>TXB2 and PGF2,.
The high production rates of PGE1 by
noncancerous and neoplastic microsomes was
surprising because PGE1 is synthesised from a
Table VIII Prostaglandin synthetase activity in vitro and oestrogen or progesterone receptor content
Tumour-noncancerous (mean +s.e.)
Oestrogen Oestrogen Progesterone Progesterone
+ve -ve +ve -ve
PGE1 2.29+ 13.93 14.96+ 18.94 -1.75+24.63 12.85+ 13.90
PGE2 -1.87+ 15.86 -35.58 +21.70 22.10+ 19.49 (P=0.046)b -34.20+ 16.39
PGF2. 2.64± 3.46 32.54+26.79 3.36+ 5.80 24.00+19.44
6-keto-PGF,a -6.50+ 6.69 -6.82+10.95 -4.92+ 8.52 -7.26+ 8.37
TXB2 -0.39+ 1.96 (P=0.056)a 4.45+ 1.46 -2.20+ 0.71 (P=0.002)c 3.71 + 1.54
aTumour TXB2 production (tumour-noncancerous tissue) tended to be higher in oestrogen -ve receptor breast
lesions.
"Tumour PGE2 production (tumour-noncancerous tissue) was higher in progesterone +ve receptor breast
lesions.
cTumour TXB2 production (tumour-noncancerous tissue) was higher in progesterone -ve receptor breast
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different precursor, dihomo-gamma-lino-lenate
(C20:3), whereas the rest of the metabolites
examined are from arachidonate, and this fatty acid
was the only prostaglandin precursor added to the
reaction mixture. Tests of cross-reactivity with
PGE1 antisera ruled out the possibility that PGE2
was being measured instead ofPGE,.
The reason for the observed elevation in yields of
immunoreactive PG-like material in breast cancer
tissue is not clearly understood. Several proposed
possibilities include: (1) increased enzyme synthetic
activity; (2) decreased catabolic activity; (3)
increased availability of precursor polyenoic acids;
(4) a breakdown in the negative feedback controls
which normally regulate PG formation (Horrobin,
1980).
In an attempt to evaluate the importance of each
of the 5 PG moieties individually, we have analysed
the relationships between tissue yields and PG
production by microsomal PG synthetase with
clinical variables such as tumour size, proportion of
positive axillary lymph nodes, distant metastases (to
liver, bone and lung), oestrogen receptor content,
progesterone receptor content and Stage of breast
malignancy. TXB2 was the only arachidonate
metabolite showing a significant relationship with
tumour size and the number of positive nodes.
However, tissue production of6-keto-PGF1,, tended
to be less in breast tumours associated with a
higher number of positive nodes.
Rolland et al. (1980) concluded from a study of
91 breast leasions that PGE2 production by
microsomal PG synthetase may be used as a
marker of high metastatic potential for neoplastic
cells in breast cancer. Bennett et al. (1975, 1977)
found that bone metastases were associated with
tumours having high levels of PG-like material.
Analysis without adjusting our PGE2 results for the
normal tissue values gives results consistent with
these reports. In addition, we have adjusted our
findings by subtracting the amount from the
normal paired sample. Such an approach takes into
consideration any variations due either to
processing or to differences between individual
specimens.
Several variables complicate the interpretation of
PG studies in breast cancer masses. Mechanical
disruption-a necessity in analysing PGs in solid
tumours-can stimulate PG production but since
ibuprofen did not alter the yield, it seems that
disruption at 2°C does not stimulate PG synthesis
by tumour tissue. Presumably normal tissues would
not synthesise PGs with this method. Tissues are
not homogenous and lymphocytes and monocytes
are present to varying extents. They probably
contribute to the PG yield but their numbers do
not correlate to the amount of PG (Bennett et al.,
1977; Rolland et al., 1980). PG production and
metabolism may vary between individuals in a way
unrelated to the neoplastic lesion. We have
accounted for this in part by including a paired
control of noncancerous breast tissue for each
breast specimen. Further studies will be necessary
to ascertain what enzymic defects or alterations
may account for the excess PG tissue content
characteristic of breast cancers.
Our preliminary results show that adjusted TXA2
production correlated with tumour size, axillary
lymph node metastases and distant metastasis,
sometimes with a concomitant decrease in PGI2.
Honn et al. (1980, 1981, 1983) have proposed that
the intravascular balance between PGI2 and TXA2
is disrupted in favor of platelet aggregation during
development of tumour cell metastasis from Lewis
lung carcinoma and B16 melanoma in mice. Such a
shift in balance of TXA2/PGI2 in favor of TXA2
was also found to favour metastasis in two
metastatic variants of a murine fibrosarcoma
(Donati et al., 1982). These findings in experimental
studies support our preliminary results and suggest
that tumour TXB2, PGI2 and PGE2 may be of
value as tests for prognostic factors in breast
cancer.
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